Quality control strategy for differentiating induced pluripotent stem cells into pancreatic β-cells before transplantation

Regenerative Medicine · Published 2026-01-02 · DOI 10.1080/17460751.2026.2634720

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/17460751.2026.2634720

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Adipose derived stem cell activation by macrophages and tendon fibroblasts · Regenerative Medicine · 2025 · Same journal
• Comparative study of the effects of subcutaneously administered umbilical cord-derived mesenchymal stem cells and exosomes derivatives on wound healing in a chemical burn model of alkaline-induced skin burns · Regenerative Medicine · 2026 · Same journal
• Revolutionizing regeneration: stem cells transform treatment of hidrotic ectodermal dysplasia (Clouston syndrome) · Regenerative Medicine · 2025 · Same journal
• Unlocking the potential of injectable hydrogels for cartilage repair · Regenerative Medicine · 2025 · Same journal
• Factors that influence trust in non-standard stem cell therapies among patients with musculoskeletal conditions: a qualitative, constructivist grounded theory study · Regenerative Medicine · 2026 · Same journal
• Implementing stem-cell therapies for limbal stem cell deficiency · Regenerative Medicine · 2026 · Same journal
• Toward improved AAV gene therapies for retinal disorders: challenges and advances · Regenerative Medicine · 2025 · Same journal
• One down but many more to go: the state of gene therapy for inherited retinal disease · Regenerative Medicine · 2025 · Same journal
• Coagulation activation and hepatic engraftment of human amnion-derived cells after intraportal transplantation in rats · Regenerative Medicine · 2025 · Same journal
• The future of hematopoietic stem cell and stem cell gene therapy for metabolic diseases · Regenerative Medicine · 2026 · Same journal